Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual MeetingGlobeNewsWire • 04/29/22
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical TrialGlobeNewsWire • 04/25/22
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North AmericaGlobeNewsWire • 04/18/22
Ocugen stock drops after FDA places clinical hold on study of COVID-19 vaccine candidate CovaxinMarket Watch • 04/12/22
3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall StreetThe Motley Fool • 04/06/22
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal DegenerationGlobeNewsWire • 04/01/22